Regeneron Pharmaceuticals (REGN) shares were down nearly 3% in recent Wednesday trading after Morgan Stanley downgraded the drugmaker to equalweight from overweight with a price target of $767.
Trading volume stood at over 732,000 shares compared with a daily average of about 1.1 million shares.
Price: 720.49, Change: -21.52, Percent Change: -2.90